Review



detection limitation of sequenom massarray  (Sequenom)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Sequenom detection limitation of sequenom massarray
    Detection Limitation Of Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc05863829-107-32-31
    Average 90 stars, based on 1 article reviews
    detection limitation of sequenom massarray - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Mass Spectrometry:

    Article Title: Genetic and Functional Dissection of the NFKB2 Gene: Implications for Milk Fatty Acid Biosynthesis in Dairy Cattle
    Article Snippet: The PCR amplification products were bi‐directionally sequenced using an ABI3730XL DNA analyzer (Applied Biosystems, Foster, CA, USA) to identify potential polymorphisms. .. Subsequently, 1065 cows were genotyped on each identified SNP by using the matrix‐assisted laser‐desorption/ionization time of flight mass spectrometry (MALDI‐TOF MS, Sequenom MassARRAY, Bioyong Technologies Inc., HK). .. Using SAS 9.2, the phenotype–genotype association analyses between the identified SNP and 24 milk FA traits was conducted with the mixed animal model below, Y ijklm = μ + G i + h j + l k + a l + b × M m + e ijklm In which, Y ijklm was the phenotypic value of each milk FA trait; μ was the overall mean; G i was the fixed effect corresponding to the genotype combination of individual i ; h j ( j = 1–23) and l k ( k = 1–4) were the fixed effect of farm j and stage of lactation l , respectively; a l was the random polygenic effect; M m ( m = 1–293) was the fixed effect of age at calving m ; b was the regression coefficient of covariate M ; and e ijklm was the random residual.

    Article Title: FCRL3 genetic variants drive autoimmune pathogenesis in multiple sclerosis and neuromyelitis optica spectrum disorders
    Article Snippet: .. This was carried out using the matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) platform (MassArray TM, Sequenom Inc., San Diego, CA, USA), following a previously established method ( ). .. PCR and extension primers were designed using MassArray Assay Design 3.1 software (Sequenom, San Diego, CA, USA) ( ).

    Mutagenesis:

    Article Title:
    Article Snippet: .. RAS/RAF mutation status of the ascites and matching tumor biopsies were determined by Sanger sequencing (ascites) and Sequenom analysis (tumor). ..

    Sequencing:

    Article Title:
    Article Snippet: .. RAS/RAF mutation status of the ascites and matching tumor biopsies were determined by Sanger sequencing (ascites) and Sequenom analysis (tumor). ..

    Polymerase Chain Reaction:

    Article Title: Method for treatment of hypertension
    Article Snippet: .. Each sample will be analyzed using 2 different methodologies, the Sequenom MassArray genotyping platform and classical PCR and gel sizing to determine insertion/deletion status. .. The Sequenom MassArray genotyping platform will be used to analyze the following sites-rs1042713, rs1042714, rs1801252, rs1801253, rs4961, rs2228576, rs1529927, rs1159744, rs2107614, rs2277869, rs12750834, rs5051, rs699, rs7079 and rs5186.

    Multiplex Assay:

    Article Title: Evidence of Genetic Isolation and Differentiation Among Historically Fragmented British Populations of Common Juniper, Juniperus communis L.
    Article Snippet: .. Of these 175 loci, 80 were selected for two multiplex Sequenom assays (Bradić et al. ), which ultimately provided data at 74 SNP loci for all samples (Table ). ..

    other:

    Article Title: Compositions and methods for treating cancer
    Article Snippet: Detection of one or more mutations may also utilize an array of probes (also referred to as a “DNA chip” assay, e.g. a GeneChip assay-Affymetrix, Santa Clara, CA).



    Similar Products

    massarray sequenom detection  (Sequenom)
    90
    Sequenom massarray sequenom detection
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc09085879-184-7-8
    Average 90 stars, based on 1 article reviews
    massarray sequenom detection - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    snps detected by sequenom massarray rs1000 platform  (Sequenom)
    90
    Sequenom snps detected by sequenom massarray rs1000 platform
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Snps Detected By Sequenom Massarray Rs1000 Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/massarray+rs1000/pm33127268-102-12-16
    Average 90 stars, based on 1 article reviews
    snps detected by sequenom massarray rs1000 platform - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mass spectrometry-based detection (sequenom massarray platform)  (Sequenom)
    90
    Sequenom mass spectrometry-based detection (sequenom massarray platform)
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometry Based Detection (Sequenom Massarray Platform), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc06107190-119-25-28
    Average 90 stars, based on 1 article reviews
    mass spectrometry-based detection (sequenom massarray platform) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    detection limitation of sequenom massarray  (Sequenom)
    90
    Sequenom detection limitation of sequenom massarray
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Detection Limitation Of Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc05863829-107-32-31
    Average 90 stars, based on 1 article reviews
    detection limitation of sequenom massarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mass spectrometric detection (sequenom massarray)  (Sequenom)
    90
    Sequenom mass spectrometric detection (sequenom massarray)
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometric Detection (Sequenom Massarray), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pm26003169-313-9-12
    Average 90 stars, based on 1 article reviews
    mass spectrometric detection (sequenom massarray) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mass spectrometric detection sequenom massarray  (Sequenom)
    90
    Sequenom mass spectrometric detection sequenom massarray
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometric Detection Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc04258414-60-7-10
    Average 90 stars, based on 1 article reviews
    mass spectrometric detection sequenom massarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system  (Sequenom)
    90
    Sequenom single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Single Nucleotide Extension Reaction With Allele Detection By Mass Spectrometry Sequenom Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/modified+single+nucleotide+extension+reaction+with+allele+detection+by+mass+spectrometry+sequenom+massarray+system/pmc06869631-79-12-14
    Average 90 stars, based on 1 article reviews
    single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

    doi: 10.1038/s41419-022-04895-6

    Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

    Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing